In response to the current monkeypox outbreak, as a leading company in biotechnology, Creative Biolabs provides one-stop virus-like particle (VLP) vaccine-based anti-monkeypox drug discovery solutions for our clients. Our services are not limited to the screening of viral surface antigen modules, the production and assembly of VLPs, and the evaluation of the anti-monkeypox efficacy of VLP vaccines. Our cutting-edge technology platform will provide the most comprehensive services with stable and high-quality results. Learn more: virus-like particle vaccine